REVER

Reverie Labs is a pharmaceutical company that utilizes advanced machine learning and artificial intelligence to engineer next-generation small molecule kinase inhibitors. The company's platform integrates computational chemistry with high-throughput synthesis to accelerate the drug discovery process, specifically focusing on brain-penetrant therapies for challenging oncology targets. By leveraging its proprietary AI infrastructure, Reverie Labs aims to develop highly selective and potent drugs that can cross the blood-brain barrier to treat primary and metastatic brain tumors. The company's pipeline primarily targets indications in non-small cell lung cancer and other solid tumors with a high propensity for central nervous system involvement.